The Antimicrobial Crisis: New Antibiotics Could Avert 230,000 Deaths Per Year

Food and Healthcare Press Releases Friday January 31, 2020 12:00
FLORENCE, Italy--31 Jan--PRNewswire/InfoQuest
Recent clinical studies presented at International Symposium organized by Fondazione Internazionale Menarini
The World Health Organization warns: invest more and invest now in research to avoid catastrophic consequences for public health

The introduction of new antibiotics would reduce the number of deaths related to superbugs from 50-55% to 10-15%: if these new antibiotics were used, one third of lives would be saved with more than 230,000 deaths averted at a global level per year, 11,000 of which only in Europe.

Recent clinical studies presented at the International Symposium organized by the Fondazione Internazionale Menarini held in Genova, where leading experts came together for an update on antimicrobial resistance, support these findings.

Every year infections related to antibiotic-resistant superbugs kill 700,000 people worldwide, 33,000 of which in Europe. Numbers which are set to rise dramatically but "through a proper and earlier use of the novel antibiotics, some of which already on the market and others potentially upcoming in the next months, we could reduce the number of deaths by one third, as demonstrated in several pivotal clinical studies involving approximately one thousand patients affected by Klebsiella pneumonia," commented Matteo Bassetti, Chairman of SITA, the Italian Society of Anti-infective Therapy.

However, these new molecules are failing to reach patients as highlighted by the recent warning issued by the WHO: today, more than ever, antimicrobial resistance is a global threat which calls for immediate solutions to be found. The decline in private investments and a lack of innovation in the development path of new antibiotics will undermine the efforts made to tackle drug-resistant infections.

It is necessary that institutions, at different levels, and the pharmaceutical industry partner to strengthen their efforts and contribute with sustainable investments to the discovery and development of innovative treatments.

"A number of these new molecules have already been approved by the Food Drug Administration and the European Medicines Agency. It's clear that there are some issues in their adoption in the clinical practice despite being recognized as lifesaving weapons, as the new cancer treatments are, and should be introduced in therapeutic algorithms to be used properly, in an empiric way, and as earlier as possible to treat critically ill patients for whom a delay in starting the right treatment will impact on mortality rates and clinical outcome,"stated Marin Kollef, Professor of Medicine at the Washington University School of Medicine.

"The successful advances in modern medicine as in surgical procedures, internal medicine, immunopathology, transplants, and cancer treatments allow for more efficient and refined procedures saving a huge number of lives but with no new antibiotics multidrug resistant hospital acquired infections threaten to reverse the miracles of the last half century," concluded Pierluigi Viale, Vice Chairman of SITA, the Italian Society of Anti-infective Therapy.

This is one of the reasons why experts are suggesting that regulatory requirements and market access procedures for new antibiotics need to be aligned with those implemented for the newest and most innovative cancer drugs, introducing simplified and accelerated approval pathways.

Logo -

Latest Press Release

One broken bone leads to another, warns IOF on World Osteoporosis Day

Today, the International Osteoporosis Foundation (IOF) calls for all adults to be alert to their risk factors for osteoporosis, a disease which can lead to a dangerous, life-threatening spiral of broken bones. A broken bone (known as a fracture) which...

MED-EL: First Surgeries Ever in Europe with a Totally Implantable Cochlear Implant

Leading hearing implant manufacturer MED-EL sets another revolutionary milestone in its long-standing history of technological innovations. On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI). It was...

Roche paves way for a new era of HCC treatment

Roche, the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics, led by Farid Bidgoli (3rd from right), General Manager, Roche Thailand, Myanmar, Cambodia and Laos, along with Saranond Assavavipapan (Left),...

Introducing Bangkok’s Most Vibrant IV Drip Bar, Anti-ageing and Aesthetics Hub - VIVID By Verita Health

Anantara Hotels, Resorts & Spas steps into the world of integrated health and wellness with the introduction of VIVID by Verita Health at Anantara Siam Bangkok Hotel. Located in the garden courtyard setting adjacent to the Bangkok jet set’s...

JUD care Launches International Partner Program for Its Portable Ward sROOM, a Revolutionary Solution for Patient Isolation

JUD care, a leading high-tech enterprise in the field of smart medical and healthcare solutions, has kicked off its international partner program for its newly-launched portable ward sRoom ("sRoom"), a revolutionary solution for patient isolation that...

Related Topics